title: Optimal drug and behavior therapy for treatment-refractory schizophrenic patients.
abstract: Thirteen treatment-refractory schizophrenic patients (10 men and three women) who were receiving more than 50 mg/day of haloperidol and who had been hospitalized for more than 1 year successfully tolerated a mean dose reduction of 63% with consequent improvement in psychopathology and side effects. The addition of intensive behavior therapy to the optimal dose of haloperidol yielded further improvements in functional behavior, such as self-care and social interaction.
authors.affiliation: Camarillo-UCLA Research Center, Camarillo State Hospital, CA 93011-6022.
authors.forename: R P
authors.initials: RP
authors.lastname: Liberman
authors.forename: T
authors.initials: T
authors.lastname: Van Putten
authors.forename: B D
authors.initials: BD
authors.lastname: Marshall
authors.forename: J
authors.initials: J
authors.lastname: Mintz
authors.forename: L
authors.initials: L
authors.lastname: Bowen
authors.forename: T G
authors.initials: TG
authors.lastname: Kuehnel
authors.forename: M
authors.initials: M
authors.lastname: Aravagiri
authors.forename: S R
authors.initials: SR
authors.lastname: Marder
mesh_terms: D000328:Adult; D001521:Behavior Therapy; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D007398:Interpersonal Relations; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy / Q000628:therapy*; D012565:Schizophrenic Psychology; D012648:Self Care
chemical_list: D006220:Haloperidol